Cargando…

Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study

PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qizhen, Lin, Kongying, Wang, Lei, Zeng, Jianxing, Liu, Hongzhi, Ding, Zongren, Zeng, Yongyi, Liu, Jingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535114/
https://www.ncbi.nlm.nih.gov/pubmed/33061610
http://dx.doi.org/10.2147/CMAR.S270467
_version_ 1783590416876044288
author Huang, Qizhen
Lin, Kongying
Wang, Lei
Zeng, Jianxing
Liu, Hongzhi
Ding, Zongren
Zeng, Yongyi
Liu, Jingfeng
author_facet Huang, Qizhen
Lin, Kongying
Wang, Lei
Zeng, Jianxing
Liu, Hongzhi
Ding, Zongren
Zeng, Yongyi
Liu, Jingfeng
author_sort Huang, Qizhen
collection PubMed
description PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT between January 2008 and December 2017: non-TACE (48) and PA-TACE (61). Propensity-score matching (PSM) was conducted in a 1:1 ratio. Recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Independent risk factors were identified by univariate and multivariate Cox regression analyses. Subgroup analysis was performed by risk-factor stratification. RESULTS: The recurrence rates in the non-TACE and PA-TACE groups were different at 6 months (50.9% vs 26.9%, P=0.03) before PSM and at 6 months (59.3% vs 26.5%, P=0.02) and 12 months (81.4% vs 37.5%, P=0.022) after PSM. OS rates of the non-TACE and PA-TACE groups were different at 6 months (74.0% vs 91.6%, P<0.001) and 12 months (61.1% vs 77.6%, P=0.01) before PSM and at 6 months (73.0% vs 96.8%, P=0.01), 12 months (52.1% vs 89.6%, P=0.001), and 18 months (33.8% vs 64.4%, P=0.034) after PSM. PA-TACE was an independent prognostic factor for both recurrence and OS before and after PSM. Subgroup analysis showed that patients with no HBV infection, tumors >5 cm, macrovascular invasion, alpha-fetoprotein (AFP) >400 ng/mL, or gamma-glutamyl transferase (GGT) >150 U/L benefited significantly from PA-TACE in terms of recurrence rates (all P<0.05). Patients with no HBV infection, multiple tumors, tumors >5 cm, macrovascular invasion, or AFP >400 ng/mL benefited significantly from PA-TACE in terms of OS (all P<0.05). CONCLUSION: PA-TACE could prolong the short-term prognosis of HCC with macroscopic BDTT and should be recommended for patients with no HBV infection, multiple tumors, tumors >5 cm, poor differentiation, macrovascular invasion, AFP >400 ng/mL, or GGT >150 U/L.
format Online
Article
Text
id pubmed-7535114
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75351142020-10-14 Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study Huang, Qizhen Lin, Kongying Wang, Lei Zeng, Jianxing Liu, Hongzhi Ding, Zongren Zeng, Yongyi Liu, Jingfeng Cancer Manag Res Original Research PURPOSE: To evaluate the effect of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) with macroscopic bile duct tumor thrombus (BDTT). PATIENTS AND METHODS: This study included 109 patients who underwent R0 resection for HCC with BDTT between January 2008 and December 2017: non-TACE (48) and PA-TACE (61). Propensity-score matching (PSM) was conducted in a 1:1 ratio. Recurrence and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Independent risk factors were identified by univariate and multivariate Cox regression analyses. Subgroup analysis was performed by risk-factor stratification. RESULTS: The recurrence rates in the non-TACE and PA-TACE groups were different at 6 months (50.9% vs 26.9%, P=0.03) before PSM and at 6 months (59.3% vs 26.5%, P=0.02) and 12 months (81.4% vs 37.5%, P=0.022) after PSM. OS rates of the non-TACE and PA-TACE groups were different at 6 months (74.0% vs 91.6%, P<0.001) and 12 months (61.1% vs 77.6%, P=0.01) before PSM and at 6 months (73.0% vs 96.8%, P=0.01), 12 months (52.1% vs 89.6%, P=0.001), and 18 months (33.8% vs 64.4%, P=0.034) after PSM. PA-TACE was an independent prognostic factor for both recurrence and OS before and after PSM. Subgroup analysis showed that patients with no HBV infection, tumors >5 cm, macrovascular invasion, alpha-fetoprotein (AFP) >400 ng/mL, or gamma-glutamyl transferase (GGT) >150 U/L benefited significantly from PA-TACE in terms of recurrence rates (all P<0.05). Patients with no HBV infection, multiple tumors, tumors >5 cm, macrovascular invasion, or AFP >400 ng/mL benefited significantly from PA-TACE in terms of OS (all P<0.05). CONCLUSION: PA-TACE could prolong the short-term prognosis of HCC with macroscopic BDTT and should be recommended for patients with no HBV infection, multiple tumors, tumors >5 cm, poor differentiation, macrovascular invasion, AFP >400 ng/mL, or GGT >150 U/L. Dove 2020-09-28 /pmc/articles/PMC7535114/ /pubmed/33061610 http://dx.doi.org/10.2147/CMAR.S270467 Text en © 2020 Huang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Qizhen
Lin, Kongying
Wang, Lei
Zeng, Jianxing
Liu, Hongzhi
Ding, Zongren
Zeng, Yongyi
Liu, Jingfeng
Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title_full Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title_fullStr Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title_full_unstemmed Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title_short Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
title_sort postoperative adjuvant transarterial chemoembolization improves short-term prognosis of hepatocellular carcinoma with bile duct tumor thrombus: a propensity-score matching study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535114/
https://www.ncbi.nlm.nih.gov/pubmed/33061610
http://dx.doi.org/10.2147/CMAR.S270467
work_keys_str_mv AT huangqizhen postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT linkongying postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT wanglei postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT zengjianxing postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT liuhongzhi postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT dingzongren postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT zengyongyi postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy
AT liujingfeng postoperativeadjuvanttransarterialchemoembolizationimprovesshorttermprognosisofhepatocellularcarcinomawithbileducttumorthrombusapropensityscorematchingstudy